Skip to main content
SpringerLink
Log in

Trovafloxacin

A Viewpoint by Keith P. Klugman

  • Adis New Drug Profile
  • Guest Commentary
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Klugman KP. The clinical relevance of in vitro resistance to penicillin, ampicillin, amoxicillin and alternate agents for the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. J Antimicrob Chemother 1996; 38 Suppl. A: 133–40

    Article  PubMed  CAS  Google Scholar 

  2. Gootz TD, Zaniewski R, Haskell S, et al. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae. Antimicrob Agents Chemother 1996; 40: 2691–7

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Microbiology, South African Institute for Medical Research, Johannesburg, South Africa

    Keith P. Klugman

Authors
  1. Keith P. Klugman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klugman, K.P. Trovafloxacin. Drugs 54, 446 (1997). https://doi.org/10.2165/00003495-199754030-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199754030-00007

Keywords

Search

Navigation